ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Risk Stratification and Safety Profile of Pharmacological Prophylaxis for Venous Thromboembolism in Postpartum Women Following Cesarean Section: A Comparative Evaluation.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveVenous thromboembolism (VTE) remains a leading cause of maternal morbidity and mortality worldwide. This study evaluated VTE risk stratification among postpartum women following cesarean section, compared the 2023 National Guidelines (NG) with the Caprini score, and assessed pharmacological thromboprophylaxis safety.MethodsA single-center prospective cohort study was conducted on 386 women undergoing cesarean delivery at Nhan Dan Gia Dinh Hospital between February and July 2025. VTE risk was independently assessed using the 2023 NG and Caprini score. Demographic characteristics, operative variables, and short-term inpatient outcomes related to low-molecular-weight heparin (LMWH) or unfractionated heparin prophylaxis were analyzed.ResultsAccording to the 2023 NG, 71.0% of patients were classified as low risk, 15.5% as intermediate risk, and 13.5% as high risk. Major risk factors included emergency cesarean delivery (45.3%), maternal age above 35 years (23.1%), and obesity (20.5%). Using the Caprini score, 45.3% met criteria for pharmacological prophylaxis, representing a 56.2% increase compared with the 2023 NG. Among 110 women receiving thromboprophylaxis, LMWH accounted for 99.1% of treatment. No severe hemorrhagic complications or thrombocytopenia were observed. Adverse events were mild and localized, mainly injection-site ecchymosis.ConclusionThe 2023 NG generated fewer pharmacological prophylaxis indications than the Caprini score in this cohort. LMWH prophylaxis showed favorable short-term inpatient safety after cesarean delivery. Because follow-up was limited to hospitalization and the study was not powered for rare VTE events, these findings should be interpreted as allocation patterns and short-term safety rather than comparative effectiveness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.